Johnson & Johnson shares climbed to a record high Tuesday, rising 1.99% to $271.20, after the healthcare giant agreed to pay $5.5 billion to settle roughly 76,000 remaining U.S. lawsuits alleging its talc products caused ovarian cancer.

The stock briefly touched an intraday record of $274.90 during Tuesday's session, extending what has become a sixth consecutive day of gains and pushing the company's year-to-date rally past 30%.

A Major Legal Overhang Finally Resolved

The proposed settlement addresses litigation that has weighed heavily on Johnson & Johnson's stock and reputation for more than a decade. The settlement removes what had been the single largest legal and reputational risk hanging over the company for more than a decade, and investors moved quickly to price out that uncertainty following Tuesday's announcement.

The scope of the agreement is substantial, though it remains contingent on broad participation from plaintiffs' attorneys. The proposed agreement covers the remaining ovarian talc litigation in federal multidistrict proceedings and related state court cases, though it is contingent on participation from plaintiff firms representing at least 95% of the outstanding claims.

Strong Options Market Activity

The scale of Tuesday's rally was also reflected in unusually heavy trading activity in the options market, where investors have shown a clear preference for bullish positioning. Options traders have shown a strong preference for calls during this run, with the stock's 50-day call-to-put volume ratio at the International Securities Exchange, Cboe Options Exchange and NASDAQ OMX........

© International Business Times